Health Canada Approves New Indication for Zytiga for Treatment of Hormone-Sensitive Prostate Cancer

Health Canada Approves New Indication for Zytiga for Treatment of Hormone-Sensitive Prostate Cancer
Health Canada recently approved Zytiga (abiraterone acetate) in combination with prednisone and androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) who may have previously received up to three months of ADT. Janssen Pharmaceutical Companies of Johnson & Johnson announced the Canadian approval just one week after the U.S. Food and Drug Administration (FDA) approved Zytiga in the United States, following results of the Phase 3 LATITUDE trial (NCT01715285). That clinical trial showed that the combo therapy reduced the risk of death by 38 percent in newly diagnosed patients compared to placebo. "Previously men with newly diagnosed metastatic prostate cancer have had limited options for first-line treatments," Fred Saad, a LATITUDE clinical investigator, said in a press release. "This latest approval for Zytiga is an exciting milestone for men, their caregivers and treating clinicians as it provides a new first-line treatment option for high-risk metastatic hormone-sensitive prostate c
Subscribe or to access all post and page content.

One comment

  1. Ben Adams says:

    I remember reading this therapy is linked to dementia so I would be scared to try with this one; I always try to go for natural remedies so I dont have to worry about the side effects, I dont have prostate cancer but I had few symptoms and I didnt pay attention to them until it got serious and tried different prostate supplements until I had to see a urologist, He prescribed me alpharise for my prostate, its 100% natural and after 5 months taking it I am happy with the results and I have not had any side effect.

Leave a Comment

Your email address will not be published. Required fields are marked *